SEC Company Response from Lite Strategy, Inc. (LITS) (CIK 0001262104) (LITS) — Jun 14, 2018
Lite Strategy, Inc. (LITS) (CIK 0001262104)
Date: June 14, 2018 · CIK: 0001262104 · Accession: 0001193125-18-192758
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225465
Letter
MEI Pharma, Inc.
3611 Valley Centre Drive, Suite 500
San Diego, CA 92130
June 14, 2018
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Abigail Jacobs
Mary Beth Breslin
Re: MEI Pharma, Inc.
Registration Statement on Form S-3
Filed June 6, 2018
File No. 333-225465
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”), hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-225465), so that such registration statement may become effective at 4:00 p.m. (Washington, D.C. time) on June 18, 2018, or as soon as practicable thereafter.
MEI PHARMA, INC.
By:
/s/ Brian G. Drazba
Name:
Brian G. Drazba
Title:
Chief Financial Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP MEI Pharma, Inc. 3611 Valley Centre Drive, Suite 500 San Diego, CA 92130 June 14, 2018 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Abigail Jacobs Mary Beth Breslin Re: MEI Pharma, Inc. Registration Statement on Form S-3 Filed June 6, 2018 File No. 333-225465 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”), hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-225465), so that such registration statement may become effective at 4:00 p.m. (Washington, D.C. time) on June 18, 2018, or as soon as practicable thereafter. MEI PHARMA, INC. By: /s/ Brian G. Drazba Name: Brian G. Drazba Title: Chief Financial Officer